Article
Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study.
Annals of surgical oncology - 1 Aug 2022
Kuo Shuenn-Wen, Chen Pei-Hsing, Lu Tzu-Pin, Chen Ke-Cheng, Liao Hsien-Chi, Tsou Kuan-Chuan, Tsai Tung-Ming, Lin Mong-Wei, Hsu Hsao-Hsun, Chen Jin-Shing
Abstract excerpt
BACKGROUND: In studies of stage IV epidermal growth factor receptor (EGFR)-mutant nonsmall-cell lung cancer (NSCLC), <10% of patients underwent surgery; thus, the effect of surgery in these patients remains unclear. We investigated whether primary lung tumor resection could improve the survival of patients with stage IV EGFR-mutant NSCLC without progression after first-line EGFR-tyrosine kinase inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.